A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Phase 3 Active not recruiting 150 enrolled Vir Biotechnology, Inc.

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a multicenter, open label, randomized Phase 3 clinical study to evaluate tobevibart + elebsiran in participants with Chronic HDV Infection not virologically suppressed with bulevirtide

Timeline

Start: 2025-07-30
Primary completion: 2026-12
Completion: 2031-07

Publications

Noack J, Anglero-Rodriguez Y, Gall J, Zhou J, LeBlanc S, Liebow A, Bakardjiev A, Hebner CM, Purcell LA, Jadhav V, Corti D, Lempp FA. Combination therapy with tobevibart and elebsiran potently reduces hepatitis B virus surface antigen levels in preclinical in vivo models. Antimicrob Agents Chemother. 2026 Mar 4;70(3):e0112725. doi: 10.1128/aac.01127-25. Epub 2026 Jan 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bulevirtide	Protein / enzyme biologic	—	Subcutaneous
Subject	Tobevibart	Monoclonal antibody	—	Subcutaneous
Subject	VIR-2218	Small interfering RNA (siRNA)	—	Subcutaneous

A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide

Summary

Timeline

Publications

Drugs

Indications